At a glance
ClinicalIndex Comparison RecordPhase 1Active· 40 target
Drug / intervention
RGT-419Bdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06299124Phase 1ActiveUpdate OverdueUpdated 17mo ago · Completion was 11mo agoEnrollment Stalled
A Phase I Study Evaluating Safety and Tolerability of RGT-419B Monotherapy in Chinese Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer or Other Solid Tumors
In Brief
A Phase 1 clinical trial evaluating RGT-419B for Breast Cancer and Advanced Solid Tumor. Active but no longer recruiting, targeting 40 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
This is a Phase 1 dose escalation and dose expansion phase I study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of RGT-419B as monotherapy in Chinese patients with HR+/HER2- advanced/metastatic breast cancer and other advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Advanced Solid Tumor
CountriesChina
Collaborators--
Timeline
Phase 1ActiveOverdue
202420252026
Enrollment StartApr 2023
First PostedMar 2024
Primary CompletionJul 2025
TodayJul 2026
First PostedMar 7, 2024
Enrollment StartApr 17, 2023
Primary CompletionJul 30, 2025
TodayJul 1, 2026
Enrollment to primary: 2.3 yearsPosted 2.3 years ago
Interventions
RGT-419Bdrug
RGT-419B will be administered orally